8年单中心170例胰腺中段切除术:含110例机器人辅助的中段胰腺切除术
机器人组手术时间和出血量均少于开放组(P<.001),总体并发症率51.8%对40%(P=.140),临床相关胰瘘34.5%对22%(P=.105),住院时间相近。结论认为胰腺中段切除术是安全有效的机器人术式,条件允许时机器人辅助可能为优选。
要点
- 机器人组手术时间162±63 min、出血88±93 mL,均少于开放组(P<.001)。
- 总体并发症率51.8%对40%、临床相关胰瘘34.5%对22%,差异均无统计学意义。
- 胰瘘仍是主要并发症,两组各1例术后死亡。
核心结论
- 胰腺中段切除术是安全有效的机器人术式,条件允许时机器人辅助可能为优选,因其手术时间和出血量更少。
- 手术时间较短可能归因于开放与机器人入路选择了不同的重建方式。
- 胰瘘仍是主要并发症。
研究设计与样本
- 机器人辅助胰腺中段切除术组110例,开放胰腺中段切除术组60例。
主要发现
- 机器人组年龄47±14 y、手术时间162±63 min、出血量88±93 mL、肿瘤大小2.4±1.3 cm。
- 开放组年龄53±14 y、手术时间208±52 min、出血量195±165 mL、肿瘤大小2.5±1.4 cm。
- 机器人组手术时间和出血量均少于开放组(P<.001)。
- 机器人组总体并发症率51.8%,开放组40%(P=.140);临床相关术后胰瘘机器人组38例(34.5%),开放组13例(22%)(P=.105)。
- 机器人组10例、开放组3例因术后出血需再手术或血管造影栓塞;平均住院时间两组相似(25±13 d对24±18 d);两组各1例术后死亡。
关键数值与推荐
- 肿瘤类型包括65例浆液性囊性肿瘤、6例黏液性囊性肿瘤、35例导管内乳头状黏液性肿瘤、29例胰腺神经内分泌肿瘤、31例实性假乳头状肿瘤、1例副神经节瘤和3例胰腺囊肿。
临床怎么用
- 在条件允许时,机器人辅助胰腺中段切除术可作为优选术式,以减少手术时间和出血量。
- 术后需重点防治胰瘘,并警惕术后出血等需再干预的并发症。
局限性
- 本研究为单中心回顾性研究,样本量有限。
- 开放与机器人入路采用不同的重建方式,可能影响手术时间比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to determine the feasibility, safety, and rate of postoperative complications after robot-assisted middle pancreatectomy compared with open middle pancreatectomy. METHODS: This retrospective study was conducted in Shanghai Ruijin Hospital, China, involving 170 patients who underwent robot-assisted middle pancreatectomy or open middle pancreatectomy from December 2010 to December 2017. Patients were in 1 of 2 groups: robot-assisted middle pancreatectomy (n = 110) and open middle pancreatectomy (n = 60). RESULTS: Among the 110 patients who underwent robot-assisted middle pancreatectomy, age, operation time, blood loss, and tumor size were 47 ± 14 y, 162 ± 63 min, 88 ± 93 mL, and 2.4±1.3 cm (mean ± standard deviation), respectively. Among the 60 patients who underwent open middle pancreatectomy, age, operation time, blood loss, and tumor size were 53 ± 14 y, 208 ± 52 min, 195 ± 165 mL, and 2.5 ± 1.4 cm (mean ± standard deviation), respectively. Mean operation time and blood loss were less in the robot-assisted middle pancreatectomy group (P < .001 each). Overall morbidity rate in the robot-assisted middle pancreatectomy group was 51.8% and 40% in open middle pancreatectomy group (P = .140). Clinically relevant postoperative pancreatic fistulas developed in 38 (34.5%) patients in the robot-assisted middle pancreatectomy group and 13 (22%) in the open middle pancreatectomy group (P = .105). A total of 10 patients in the robot-assisted middle pancreatectomy group and 3 patients in the open middle pancreatectomy group required a reoperation or angiographic embolization because of postoperative bleeding. The mean hospital stay was similar in the 2 groups (25 ± 13 d versus and 24 ± 18 d). There was 1 postoperative death in each group because of postoperative bleeding and a pulmonary embolus, respectively. The tumors in this study included 65 serous cystic neoplasms, 6 mucinous cystic neoplasms, 35 intraductal papillary mucinous neoplasms, 29 pancreatic neuroendocrine tumors, 31 solid pseudopapillary tumors, 1 paraganglioma, and 3 pancreatic cysts. CONCLUSION: Middle pancreatectomy is a safe and effective robotic operative procedure, and when possible, robot-assisted middle pancratectomy might be the preferred method, because it was associated with decreased operative time and decreased blood loss. The lesser operation time might be attributed to different reconstruction methods that were chosen in the open and robotic approach. Pancreatic fistula remains the major complication.
引用
- Shi Y, Jin J, Huo Z, et al. An 8-year single-center study: 170 cases of middle pancreatectomy, including 110 cases of robot-assisted middle pancreatectomy. Surgery. 2019. PMID: 31629541. doi:10.1016/j.surg.2019.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。